Early physics with the ATLAS and CMS detectors at LHC

The Large Hadron Collider (LHC) at CERN in Geneva (Switzerland) will go into operation in the coming months and will soon enable us to analyse the highest energy collisions ever produced at an accelerator. With a design integrated luminosity of up to 100/fb per year and a centre-of-mass energy of 14 TeV it will not only allow us to probe the Standard Model beyond the TeV scale but also search for new phenomena such as the Higgs boson, supersymmetric particles, extra spatial dimensions etc. This article summarises a few selected analyses which are foreseen to be performed with the first 0.01 to 1/fb

Data Preservation at LEP

The four LEP experiments ALEPH, DELPHI, L3 and OPAL successfully recorded e+e- collision data during the years 1989 to 2000. As part of the ordinary evolution in High Energy Physics, these experiments can not be repeated and their data is therefore unique. This article briefly reviews the data preservation efforts undertaken by the four experiments beyond the end of data taking. The current status of the preserved data and associated tools is summarised.Comment: 7 pages, contribution to proceedings of the "First Workshop on Data Preservation and Long Term Analysis in HEP

Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy

<p>Abstract</p> <p>Background</p> <p>Diagnosis and treatment of ovarian cancer (OC) entail severe symptom burden and a significant loss of quality of life (QOL). Somatic and psychological impairments may persist well beyond active therapy. Although essential for optimal symptom management as well as for the interpretation of treatment outcomes, knowledge on the course of QOL-related issues is scarce. This study aimed at assessing the course of depressive symptoms, anxiety, fatigue and QOL in patients with OC over the course of chemotherapy until early after-care.</p> <p>Methods</p> <p>23 patients were assessed longitudinally (eight time points) with regard to symptom burden (depression, anxiety, fatigue, and QOL) by means of patient-reported outcome instruments (HADS, MFI-20, EORTC QLQ-C30/-OV28) and clinician ratings (HAMA/D) at each chemotherapy cycle and at the first two aftercare visits.</p> <p>Results</p> <p>Statistically significant decrease over time was found for depressive symptoms and anxiety as well as for all fatigue scales. With regard to QOL, results indicated significant increase for 11 of 15 QOL scales, best for Social (effect size = 1.95; <it>p </it>< 0.001), Emotional (e.s. = 1.62; <it>p </it>< 0.001) and Physical Functioning (e.s. = 1.47; <it>p </it>< 0.001). Abdominal Symptoms (e.s. = 1.01; <it>p </it>= 0.009) decreased, Attitudes towards Disease and Treatment (e.s. = 1.80; <it>p </it>< 0.001) improved significantly over time. Analysis of Sexual Functioning was not possible due to a high percentage of missing responses (61.9%).</p> <p>Conclusions</p> <p>The present study underlines the importance of longitudinal assessment of QOL in order to facilitate the identification of symptom burden in OC patients. We found that patients show high levels of fatigue, anxiety and depressive symptoms and severely impaired QOL post-surgery (i.e. at start of chemotherapy) but condition improves considerably throughout chemotherapy reaching nearly general population symptoms levels until aftercare.</p